Videos

TTLC 2026 spotlights next-gen lung cancer therapies, co-mutation strategies, and ctDNA monitoring—insights beyond CME for what’s coming next.

In this episode, Andrew A. Lane, MD, PhD, Dana-Farber Cancer Institute, discusses the future of BPCDN treatment and how a collaborative care model should play a role in this rare disease.

In this episode, Andrew A. Lane, MD, PhD, Dana-Farber Cancer Institute, offers an overview of pivekimab sunirine and CD123-directed antibody-drug conjugates (ADCs) in the BPDCN pipeline.

The current research frontier in blastic plasmacytoid dendritic cell neoplasm (BPDCN) is moving toward combination triplet therapies. Andrew A. Lane, MD, PhD, Dana-Farber Cancer Institute, explores the clinical rationale for triplet regimens combining tagraxofusp-erzs (Elzonris), azacitidine (Vidaza), and ventoclax (Venclexta).

In this episode, Andrew A. Lane, MD, PhD, Dana-Farber Cancer Institute, outlines monitoring parameters and intervention strategies required for patient safety following treatment with tagraxofusp for blastic plasmacytoid dendritic cell neoplasm (BPDCN).

BPDCN breakthroughs: CD123-targeting tagraxofusp and venetoclax-azacitidine combinations boost remissions, limit myelosuppression, and help reach transplant.

Spot BPDCN fast: skin-first clues, CD123/CD4/CD56 triad, mandatory CNS staging, and transplant-focused remission strategy.

Explore rising HPV-driven anal cancer burden and NCCN first-line choices, with trial data guiding chemo-immunotherapy patient selection.

Sagar Lonial, MD, discusses the evolving role of cereblon E3 ligase modulators (CELMoDs) in the treatment of multiple myeloma.

Short-course enzalutamide in recurrent prostate cancer slashes PSA, but PSMA-PET tumor volume misleads, raising overtreatment concerns.

Rahul Banerjee, MD, discusses the rationale for potential therapeutic strategies to address T-cell exhaustion following CAR T-cell therapy in multiple myeloma.

Explore the NETTER-1 study's findings on PRRT for neuroendocrine tumors, including benefits, risks, and alternative treatments like everolimus.

Two biomarkers, KIM-1 and ctDNA, may lead to the development of a prognostic tool.

The phase 3 IMvigor011 trial represents a landmark shift toward personalized, biomarker-driven adjuvant therapy in muscle-invasive bladder cancer.

Gemcitabine-iDRS did not show superior bladder-intact event-free survival over chemoradiotherapy and there were no patient subgroups that suggest further evaluation in subsequent studies.

Phase 2 Daro-PET tests short-course darolutamide to boost PSMA PET signal in high-risk localized prostate cancer, guiding improved imaging interpretation.

Antonio Ocejo, MD, discussed a multi-institutional analysis focusing on the clinical outcomes and tolerability of ipilimumab and nivolumab in patients with metastatic RCC.

AI begins transforming precision oncology, speeding drug target discovery with AlphaFold and cutting clinical trial paperwork from months to days.

Trial finds CAR‑T approach shows minimal CRS and no neurotoxicity or prolonged cytopenia, enabling safer treatment for older, frail patients.

Healthcare professionals emphasize the importance of balancing treatment options with patient priorities, focusing on individual goals and quality of life.

Final overall survival data for PEACE-3 (NCT02194842) evaluating the combination of enzalutamide (Xtandi) and radium-223 (Xofigo) will be presented at the 2026 ASCO GU Cancers Symposium.

AI accelerates precision oncology, turning genomic data into smarter, targeted cancer treatments, fewer adverse effects, and faster decisions for personalized care.

Anticipated findings from the LITESPARK-011 trial (NCT04586231) to be presented during the 2026 ASCO Genitourinary Cancers Symposium could shift second-line approaches in metastatic renal cell carcinoma.

Rahul Banerjee, MD, discusses a potential mechanism for checkpoint inhibition following CAR T-cell therapy in patients with multiple myeloma.

Actinium-225 is a targeted and highly-potent alpha emitter that holds promise for patients who do not respond to lutetium-177 therapy.

Bone-protecting therapies are an important part of delivering optimal care in patients with prostate cancer who are treated with androgen-deprivation therapy.

The rationale for KEYNOTE-B15 is to determine whether perioperative enfortumab Bedouin (Padcev) and pembrolizumab (Keytruda) can improve outcomes in patients with muscle-invasive bladder cancer compared with standard of care.

Macrophage cell therapy may skip lymphodepleting chemo, reducing toxicity and secondary cancer risk for heavily pretreated, frail patients.